Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now?

Glaucoma is the second most common cause of blindness, affecting 70~80 million people around the world. The death of retinal ganglion cells (RGCs) is the main cause of blindness related to this disease. Current therapies do not provide enough protection and regeneration of RGCs. A novel opportunity...

Descripción completa

Detalles Bibliográficos
Autores principales: Daliri, Karim, Ljubimov, Alexander V., Hekmatimoghaddam, Seyedhossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Stem Cell Research 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741193/
https://www.ncbi.nlm.nih.gov/pubmed/28844129
http://dx.doi.org/10.15283/ijsc17029
Descripción
Sumario:Glaucoma is the second most common cause of blindness, affecting 70~80 million people around the world. The death of retinal ganglion cells (RGCs) is the main cause of blindness related to this disease. Current therapies do not provide enough protection and regeneration of RGCs. A novel opportunity for treatment of glaucoma is application of technologies related to stem cell and gene therapy. In this perspective we will thus focus on emerging approaches to glaucoma treatment including stem cells and gene therapy.

Ejemplares similares